TFF Pharmaceuticals — Corporate Update (August 2023)
25 slides from TFF Pharmaceuticals's corporate update, Aug 15, 2023
Slide 1: Corporate Update August 2023
1 NASDAQ: TFFP Corporate Update August 2023 BETTER DELIVERY, BETTER THERAPY | Powerful Drug Delivery Solutions
Slide 2: Safe Harbor Statement
Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This document contains forward - looking statements concerning TFF Pharmaceuticals, Inc . (“TFF”, the “Company,” “we,” “us,” and “our”) . The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,”
Slide 3: Investment Highlights
Investment Highlights Experienced Management; IP Protection • Experienced senior management team with outstanding track record of success in a diverse set of competencies and related disciplines • Robust IP estate with over 120 patents issued or pending Strong Internal Pipeline • TFF VORI (inhaled v
Slide 4: Thin Film Freezing Process
Thin Film Freezing Process Bulk Drug Material x Use proprietary combination of freezing rate and liquid surface to volume ratio x Confers advantages in engineering particles for various routes of administration x Stabilizes biologics not achievable with other process technologies Drying and Lyophili
Slide 5: New Vision for TFF
New Vision for TFF Transform from a technology platform company reliant on licensing Previous Focus: • A technology platform company generating value creation from licensing TFF technology to big pharma and biotech companies New Vision: • A product development company focused on bringing to market h
Slide 6: TFF Investment Opportunity
TFF Investment Opportunity New Corporate Strategy • Leverage our R&D talent and unique technology to accelerate the development of proprietary drugs • Singular focus on advancing therapies that can significantly improve upon the standard of care • Products that can be marketed with a small, specialt
Slide 7: Disciplined Approach to Cash Management
Disciplined Approach to Cash Management • Budget cuts instituted in Q1 and Q2 2023 extend cash runway into December 2023 • Hiring slowed and existing headcount reduced • Consulting contracts restructured • Reduction in professional fees and investor relations • Paused market research and public rela
Slide 8: TFF VORI Voriconazole Inhalation Powder Clinical Development Program
TFF VORI Voriconazole Inhalation Powder Clinical Development Program 8
Slide 9: TFF VORI: Update on Clinical Development Strategy
TFF VORI: Update on Clinical Development Strategy Prior Approach: • Focus on invasive pulmonary aspergillosis • 140,000 cases per year worldwide (treatment and prevention) • ≥ $1B TFF VORI peak forecast global sales • Differentiate on safety, tolerability, and drug - drug interactions • Focus on tre
Slide 10: TFF VORI: Clinical Development Rationale
TFF VORI: Clinical Development Rationale TFF VORI is in Phase 2 development for the treatment of pulmonary fungal infections including invasive pulmonary aspergillosis (IPA) • IPA primarily impacts immune compromised patients (hematologic malignancies, solid organ, and stem cell transplant recipient
Slide 11: TFF VORI: Phase 1 and compassionate use experience
TFF VORI: Phase 1 studies and compassionate use experience provided safety, tolerability, pharmacokinetic, and early efficacy data Available Compassionate use data: Two lung transplant recipients with history of recurrent pulmonary fungal infections and toxicities to systemic available standard of c
Slide 12: TFF VORI: Program Execution
TFF VORI: Program Execution Confidential 12 Identified challenges: • First patient was originally projected in the Phase 2 study in 8/22; first site not activated until end of December 2022; Significant CRO challenges Progress since January of 2023: • Changed the CRO project manager and the site act
Slide 13: Phase 2 Pre-Screening Status
Significant rise in the number of pre - screened patients (As of July 31, 2023): • Pre - screening in the first 4 months (December to March) = 9 • Pre - screening in the last 4 months (April to July) = 44 • Pre - screening in April = 5 • Pre - screening in May = 11 • Pre - screening in June = 12 • P
Slide 14: TFF VORI: Phase 2 and EAP Enrollment Projection
TFF VORI: Phase 2 and EAP Enrollment Projection 0 5 10 15 20 25 Dec Jan Feb Mar Apr May Jun Projected Cumulative Enrollment Jul Aug Sep Oct Nov Dec Jan Actual Cumulative Enrollment Feb Mar Apr Patients Enrolled Confidential 14
Slide 15: TFF VORI: Expanded Access Program
TFF VORI: Expanded Access Program • Expanded Access Program enrolls patients with the following diagnoses who have limited or no other treatment options or who have had unfavorable response to adequate standard of care therapy: • Pulmonary aspergillosis: • Invasive pulmonary aspergillosis (IPA) • Ch
Slide 16: TFF VORI: Expanded Access Program
TFF VORI: Expanded Access Program • Company policy posted on the website introducing the availability of the expanded access program • Program listed on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT05897294 • Program listed on the Reagan - Udall Foundation Expanded Access Navigator: ht
Slide 17: TFF TAC Tacrolimus Inhalation Powder Clinical Development Program
TFF TAC Tacrolimus Inhalation Powder Clinical Development Program 17
Slide 18: TFF TAC: Background Information
TFF TAC: Background Information TFF TAC is in Phase 2 development for prevention of rejection in lung transplant recipients; ~40,000 new and existing patients worldwide with ≥ $1 billion peak TFF TAC global forecast • Tacrolimus is first - line calcineurin inhibitor for prevention of rejection in lu
Slide 19: TFF TAC: Phase 1 Results and Phase 2 Planning
TFF TAC: Phase 1 study provided safety, tolerability and pharmacokinetic data and enabled Phase 2 planning Phase 1 Results: • Phase 1a healthy volunteer study (n=57 subjects): • Doses up to 5 mg (single dose) and 1.5 mg (repeated dose) daily were generally well tolerated • No dose - related increase
Slide 20: TFF TAC: Phase 2 Status
Sites (As of July 25, 2023) • 1 site activated and actively enrolling; 3 patients enrolled • 2nd site activation expected in August • 3rd site activation projected in September Patients • Significant learning about how to transition patients from oral tacrolimus to TFF TAC • Goal is to prevent rejec
Slide 21: TFF TAC: Phase 2 Enrollment Projection
0 5 10 15 20 25 Dec Jan Feb Mar Apr May Jun Jul * Aug Sep Oct Nov Dec Jan Actual Cumulative Enrollment Feb Mar Apr Patients Enrolled Projected Cumulative Enrollment *1 subject screened in July, enrolled in August Confidential 21 TFF TAC: Phase 2 Enrollment Projection
Slide 22: New Opportunities Leveraging TFF's Platform with Non-Dilutive Funding
22 New Opportunities Leveraging TFF’s Platform with Non - Dilutive Funding
Slide 23: Recent Government Collaborations
May 4, 2023 TFF Pharmaceuticals enters into CRADA with the National Institute of Environmental Health Sciences (NIEHS) to develop dry powder formulations of Hyaluronan to prevent and treat respiratory diseases. May 1, 2023 TFF Pharmaceuticals receives additional funding from Leidos to advance next g
Slide 24: Key Takeaways
Key Takeaways Revolutionary platform enabling inhalable drug delivery across the entire spectrum of pharmaceutical agents (small & large molecules, biologics, vaccines, mRNA), targeting multiple $1 billion+ markets x Ability to convert a wide range of poorly water - soluble drugs into inhalable dry
Slide 25: Thank You
TFF, PHARMACEUTICALS. THANK YOU